MedPath

A Study to Evaluate Immunotherapy Combinations in Participants With Lung Cancer

Phase 1
Completed
Conditions
Non Small Cell Lung Cancer Metastatic
Non Small Cell Lung Cancer
Nonsquamous Nonsmall Cell Neoplasm of Lung
Sensitizing EGFR Gene Mutation
Interventions
Registration Number
NCT03846310
Lead Sponsor
Arcus Biosciences, Inc.
Brief Summary

This is a Phase 1/1b, multicenter, open-label, dose-escalation and dose-expansion study to evaluate the safety, tolerability, pharmacokinetic (PK), pharmacodynamic, and clinical activity of etrumadenant (AB928) in combination with carboplatin and pemetrexed, with or without an anti-PD-1 antibody (pembrolizumab or zimberelimab), in participants with non-squamous Non-Small Cell Lung Cancer (NSCLC).

Detailed Description

In the dose-escalation phase, escalating doses of etrumadenant in combination with carboplatin and pemetrexed at standard doses (Arm A), and etrumadenant in combination with carboplatin, pemetrexed and pembrolizumab (Arm B), may be assessed in participants with advanced NSCLC. Eligible participants will receive oral administration of etrumadenant as well as IV infused carboplatin, pemetrexed, with or without pembrolizumab in this phase. The recommended dose for expansion (RDE) of etrumadenant will be determined upon completion of the dose-escalation phase.

In the dose-expansion phase, zimberelimab in combination with carboplatin and pemetrexed (Arm 1), and etrumadenant at RDE in combination with carboplatin, pemetrexed, and zimberelimab (Arm 2) may be assessed in eligible NSCLC participants who harbor an EGFR mutation and have progressed on EGFR Tyrosine Kinase Inhibitor (TKI) treatment(s).

Overall duration of treatment will depend on how well the treatment is tolerated.

Treatment may continue until unacceptable toxicity or progressive disease or other reasons specified in the protocol.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
77
Inclusion Criteria
  • Male or female participants; age ≥ 18 years

  • Pathologically confirmed nonsquamous NSCLC that is metastatic, locally advanced, or recurrent with progression

  • Arm A participants must fulfill one of the following:

    • Participant has a genetic alteration (mutation or rearrangement) and has received all available targeted therapy. Previous treatment with chemotherapy or PD-1/-L1 therapy is not allowed.
    • Participant has not received any therapy for the disease under study and standard therapy is refused.
    • Participant has progressed on PD-1/-L1 therapy (monotherapy or combination regimen). Previous treatment with chemotherapy is not allowed.
    • Participant has progressed on PD-1/-L1 therapy (monotherapy or combination regimen) and has received less than 4 cycles of carboplatin/pemetrexed and further chemotherapy is appropriate.
    • Participant has received any number of prior treatments and is without alternative or curative therapy.
  • Arm B participants must fulfill one of the following:

    • Participant has a genetic alteration (mutation or rearrangement) and has received all available targeted therapy. Previous treatment with chemotherapy or PD-1/-L1 therapy is not allowed.
    • Participant has not received any therapy for the disease under study and standard therapy is refused.
    • Participant has received any number of prior treatments and is without alternative or curative therapy.
  • Arm 1 and Arm 2 participants must have a sensitizing epidermal growth factor receptor (EGFR) mutation with disease progression or treatment intolerance after one or more approved TKIs. Previous treatment with chemotherapy or PD-1/L-1 therapy is not allowed.

  • No TKI therapy within 5 days of Cycle 1 Day 1

  • The last dose of previous investigational therapy is at least 4 weeks or 5 half-lives prior to Cycle 1 Day 1.

  • Must have at least 1 measurable lesion per Response Evaluation Criteria in Solid Tumors (RECIST v1.1)

  • Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1.

  • Confirm that an archival tissue sample is available and ≤ 24 months old; if not, a new biopsy of a tumor lesion should be obtained at screening

  • Adequate organ and marrow function

Exclusion Criteria
  • Use of any live vaccines against infectious diseases within 4 weeks (28 days) of initiation of investigational product

  • Is pregnant or breastfeeding or expecting to conceive or father children within the projected duration of the study, starting with the pre-screening or screening visit through 30 days after the last dose of etrumadenant, 90 days after the last dose of zimberelimab or pembrolizumab, or 6 months after the last dose of pemetrexed, whichever is longer

  • Any active autoimmune disease or a documented history of autoimmune disease or syndrome that required systemic treatment in the past 2 years (ie, with use of disease-modifying agents, corticosteroids, or immunosuppressive drugs), except for vitiligo or resolved childhood asthma/atopy

  • Prior malignancy active within the previous 2 years except for locally curable cancers that have been apparently cured, such as basal or squamous cell skin cancer, superficial bladder cancer, or carcinoma in situ of the cervix, breast, or prostate cancer

  • Prior use of an adenosine pathway targeting agent

  • Due to potential for drug-drug interactions with etrumadenant, participants must not have had:

    • Treatment with breast cancer resistance protein substrates or P-glycoprotein with a narrow therapeutic window, administered orally within 4 weeks or 5 half-lives of the drug (whichever is longer) prior to initiation of study treatment.
    • Treatment with known strong cytochrome P450 3A4 (CYP3A4) inducers and strong CYP3A4 inhibitors within 4 weeks or 5 half-lives of the drug (whichever is longer) prior to initiation of study treatment

Study & Design

Study Type
INTERVENTIONAL
Study Design
SEQUENTIAL
Arm && Interventions
GroupInterventionDescription
Dose Expansion Arm 1CarboplatinZimberelimab will be administered in combination with standard carboplatin and pemetrexed chemotherapy regimen in participants with Non-Small Cell Lung Cancer harboring a sensitizing EGFR mutation.
Dose Expansion Arm 1PemetrexedZimberelimab will be administered in combination with standard carboplatin and pemetrexed chemotherapy regimen in participants with Non-Small Cell Lung Cancer harboring a sensitizing EGFR mutation.
Dose Expansion Arm 2CarboplatinThe etrumadenant at RDE determined from the dose escalation phase will be administered in combination with standard carboplatin and pemetrexed chemotherapy regimen and zimberelimab in participants with Non-Small Cell Lung Cancer harboring a sensitizing EGFR mutation.
Dose Escalation Arm AEtrumadenantDose escalation is a 3+3 design, including a Dose Limiting Toxicity (DLT) evaluation period. The RDE of etrumadenant will be determined in this part with escalating doses of etrumadenant in combination with standard doses of carboplatin/pemetrexed chemotherapy regimen in participants with Non-Small Cell Lung Cancer.
Dose Escalation Arm ACarboplatinDose escalation is a 3+3 design, including a Dose Limiting Toxicity (DLT) evaluation period. The RDE of etrumadenant will be determined in this part with escalating doses of etrumadenant in combination with standard doses of carboplatin/pemetrexed chemotherapy regimen in participants with Non-Small Cell Lung Cancer.
Dose Escalation Arm APemetrexedDose escalation is a 3+3 design, including a Dose Limiting Toxicity (DLT) evaluation period. The RDE of etrumadenant will be determined in this part with escalating doses of etrumadenant in combination with standard doses of carboplatin/pemetrexed chemotherapy regimen in participants with Non-Small Cell Lung Cancer.
Dose Escalation Arm BCarboplatinDose escalation is a 3+3 design, including a Dose Limiting Toxicity (DLT) evaluation period. The RDE of etrumadenant will be determined in this part with escalating doses of etrumadenant in combination with standard doses of carboplatin/pemetrexed chemotherapy regimen and pembrolizumab in participants with Non-Small Cell Lung Cancer.
Dose Escalation Arm BPemetrexedDose escalation is a 3+3 design, including a Dose Limiting Toxicity (DLT) evaluation period. The RDE of etrumadenant will be determined in this part with escalating doses of etrumadenant in combination with standard doses of carboplatin/pemetrexed chemotherapy regimen and pembrolizumab in participants with Non-Small Cell Lung Cancer.
Dose Escalation Arm BPembrolizumabDose escalation is a 3+3 design, including a Dose Limiting Toxicity (DLT) evaluation period. The RDE of etrumadenant will be determined in this part with escalating doses of etrumadenant in combination with standard doses of carboplatin/pemetrexed chemotherapy regimen and pembrolizumab in participants with Non-Small Cell Lung Cancer.
Dose Expansion Arm 1ZimberelimabZimberelimab will be administered in combination with standard carboplatin and pemetrexed chemotherapy regimen in participants with Non-Small Cell Lung Cancer harboring a sensitizing EGFR mutation.
Dose Expansion Arm 2ZimberelimabThe etrumadenant at RDE determined from the dose escalation phase will be administered in combination with standard carboplatin and pemetrexed chemotherapy regimen and zimberelimab in participants with Non-Small Cell Lung Cancer harboring a sensitizing EGFR mutation.
Dose Expansion Arm 2PemetrexedThe etrumadenant at RDE determined from the dose escalation phase will be administered in combination with standard carboplatin and pemetrexed chemotherapy regimen and zimberelimab in participants with Non-Small Cell Lung Cancer harboring a sensitizing EGFR mutation.
Dose Escalation Arm BEtrumadenantDose escalation is a 3+3 design, including a Dose Limiting Toxicity (DLT) evaluation period. The RDE of etrumadenant will be determined in this part with escalating doses of etrumadenant in combination with standard doses of carboplatin/pemetrexed chemotherapy regimen and pembrolizumab in participants with Non-Small Cell Lung Cancer.
Dose Expansion Arm 2EtrumadenantThe etrumadenant at RDE determined from the dose escalation phase will be administered in combination with standard carboplatin and pemetrexed chemotherapy regimen and zimberelimab in participants with Non-Small Cell Lung Cancer harboring a sensitizing EGFR mutation.
Primary Outcome Measures
NameTimeMethod
Percentage of participants with Adverse EventsFrom first study treatment administration until up to 90 days after the last dose (Approximately 1 year)
Percentage of participants who experience a Dose Limiting ToxicityFrom first study treatment administration through Day 21
Secondary Outcome Measures
NameTimeMethod
Plasma concentration of etrumadenantRecorded at baseline (screening), during the first 4 cycles of treatment (4 months) and 30 days post last dose (i.e. in total approximately 5 months).
Serum concentration of zimberelimabRecorded at baseline (screening), during the first 4 cycles of treatment (4 months) and 30 days post last dose (i.e. in total approximately 5 months).
Percentage of Participants with Disease Control (complete response, partial response, or stable disease) for >6 monthsFrom study enrollment until disease progression or loss of clinical benefit (up to approximately 3-5 years)
Progression Free Survival (PFS)From start of treatment up to the first occurrence of progressive disease or death from any cause, whichever occurs first (up to approximately 3-5 years)
Duration of ResponseFrom the date of first occurrence of a documented objective response to first documentation of disease progression or death from any cause, whichever occurs first (up to approximately 3-5 years)
Percentage of participants with Objective ResponseFrom study enrollment until participant discontinuation, first occurrence of progressive disease, or death from any cause, whichever occurs first (up to approximately 3-5 years)
Percentage of participants with anti-drug antibodies to zimberelimabRecorded at baseline (screening), during the first 4 cycles of treatment (4 months) and 30 days post last dose (i.e. in total approximately 5 months).

Trial Locations

Locations (22)

Chungbuk National University Hospital

🇰🇷

Cheongju-si, Korea, Republic of

Bundang CHA Medical Center

🇰🇷

Seongnam-si, Korea, Republic of

Severance Hospital, Yonsei University Health System

🇰🇷

Seoul, Korea, Republic of

Asan Medical Centre

🇰🇷

Seoul, Korea, Republic of

Seoul St. Mary's Hospital

🇰🇷

Seoul, Korea, Republic of

Seoul National University Hospital

🇰🇷

Suwon, Korea, Republic of

National University Hospital

🇸🇬

Singapore, Singapore

National Cancer Centre Singapore

🇸🇬

Singapore, Singapore

Changhua Christian Hospital

🇨🇳

Changhua, Taiwan

Taipei Medical University - Shuang Ho Hospital

🇨🇳

New Taipei City, Taiwan

Chi Mei Hospital, Liouying

🇨🇳

Tainan City, Taiwan

National Taiwan University Hospital

🇨🇳

Taipei City, Taiwan

Tri Service General Hospital

🇨🇳

Taipei City, Taiwan

Arizona Cancer Research Center (ACRC)

🇺🇸

Tucson, Arizona, United States

SCRI Florida Cancer Specialists - South

🇺🇸

Fort Myers, Florida, United States

SCRI Florida Cancer Specialists - North

🇺🇸

Tavares, Florida, United States

SCRI Tennessee Oncology - Nashville

🇺🇸

Nashville, Tennessee, United States

USO Texas Oncology - Dallas (Baylor Charles A. Sammons Cancer Center)

🇺🇸

Dallas, Texas, United States

USO Virginia Cancer Specialist

🇺🇸

Fairfax, Virginia, United States

USO Virginia Oncology Associates

🇺🇸

Norfolk, Virginia, United States

Medical Oncology Associates/Summit Cancer Center

🇺🇸

Spokane, Washington, United States

The Catholic University of Korea St. Vincent Hospital

🇰🇷

Suwon-si, Gyeonggi, Korea, Republic of

© Copyright 2025. All Rights Reserved by MedPath